IMS 2022 | Bendamustine-rituximab vs ibrutinib as frontline therapy in Waldenström’s macroglobulinemia
Steven Treon
• 25 Aug 2022
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the results of a retrospective study comparing bendamustine plus rituximab (BR) versus ibrutinib in patients with Waldenström’s macroglobulinemia (WM) in the first-line setting. Whilst the study showed that there was no significant difference in progression-free survival (PFS) or overall survival (OS) between the two groups, Prof. Treon explains that it is important to select the appropriate treatment regimen depending on each patient’s characteristics. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
